nodes	percent_of_prediction	percent_of_DWPC	metapath
Rivaroxaban—ABCB1—kidney cancer	0.238	1	CbGaD
Rivaroxaban—CYP3A5—Temsirolimus—kidney cancer	0.0695	0.135	CbGbCtD
Rivaroxaban—ABCB1—Temsirolimus—kidney cancer	0.0453	0.0876	CbGbCtD
Rivaroxaban—CYP3A4—Everolimus—kidney cancer	0.0401	0.0777	CbGbCtD
Rivaroxaban—CYP3A4—Temsirolimus—kidney cancer	0.0271	0.0525	CbGbCtD
Rivaroxaban—CYP3A5—Erlotinib—kidney cancer	0.0261	0.0505	CbGbCtD
Rivaroxaban—CYP3A5—Paclitaxel—kidney cancer	0.0239	0.0462	CbGbCtD
Rivaroxaban—ABCB1—Pazopanib—kidney cancer	0.0238	0.046	CbGbCtD
Rivaroxaban—ABCB1—Dactinomycin—kidney cancer	0.0217	0.0421	CbGbCtD
Rivaroxaban—CYP3A5—Sorafenib—kidney cancer	0.0212	0.041	CbGbCtD
Rivaroxaban—CYP3A5—Vincristine—kidney cancer	0.0206	0.0398	CbGbCtD
Rivaroxaban—ABCB1—Gemcitabine—kidney cancer	0.0172	0.0333	CbGbCtD
Rivaroxaban—CYP3A5—Sunitinib—kidney cancer	0.0172	0.0333	CbGbCtD
Rivaroxaban—ABCB1—Erlotinib—kidney cancer	0.017	0.0328	CbGbCtD
Rivaroxaban—ABCB1—Paclitaxel—kidney cancer	0.0155	0.0301	CbGbCtD
Rivaroxaban—CYP3A4—Pazopanib—kidney cancer	0.0142	0.0276	CbGbCtD
Rivaroxaban—ABCB1—Sorafenib—kidney cancer	0.0138	0.0267	CbGbCtD
Rivaroxaban—ABCB1—Vinblastine—kidney cancer	0.0136	0.0264	CbGbCtD
Rivaroxaban—ABCB1—Vincristine—kidney cancer	0.0134	0.0259	CbGbCtD
Rivaroxaban—ABCB1—Sunitinib—kidney cancer	0.0112	0.0216	CbGbCtD
Rivaroxaban—CYP3A4—Erlotinib—kidney cancer	0.0102	0.0197	CbGbCtD
Rivaroxaban—CYP3A4—Paclitaxel—kidney cancer	0.0093	0.018	CbGbCtD
Rivaroxaban—ABCB1—Doxorubicin—kidney cancer	0.00837	0.0162	CbGbCtD
Rivaroxaban—CYP3A4—Sorafenib—kidney cancer	0.00826	0.016	CbGbCtD
Rivaroxaban—CYP3A4—Vinblastine—kidney cancer	0.00816	0.0158	CbGbCtD
Rivaroxaban—CYP3A4—Vincristine—kidney cancer	0.00802	0.0155	CbGbCtD
Rivaroxaban—CYP3A4—Sunitinib—kidney cancer	0.0067	0.013	CbGbCtD
Rivaroxaban—CYP3A4—Doxorubicin—kidney cancer	0.00501	0.00971	CbGbCtD
Rivaroxaban—CYP2J2—nephron tubule—kidney cancer	0.000222	0.157	CbGeAlD
Rivaroxaban—F10—cardiac atrium—kidney cancer	0.000221	0.156	CbGeAlD
Rivaroxaban—CYP3A4—urine—kidney cancer	0.000218	0.154	CbGeAlD
Rivaroxaban—CYP2J2—cardiac atrium—kidney cancer	0.000181	0.128	CbGeAlD
Rivaroxaban—Gastrointestinal pain—Sunitinib—kidney cancer	0.000143	0.00068	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Capecitabine—kidney cancer	0.000143	0.00068	CcSEcCtD
Rivaroxaban—Pruritus—Erlotinib—kidney cancer	0.000143	0.00068	CcSEcCtD
Rivaroxaban—Fatigue—Dactinomycin—kidney cancer	0.000143	0.000679	CcSEcCtD
Rivaroxaban—Epistaxis—Capecitabine—kidney cancer	0.000143	0.000678	CcSEcCtD
Rivaroxaban—Pain—Dactinomycin—kidney cancer	0.000142	0.000673	CcSEcCtD
Rivaroxaban—Agranulocytosis—Capecitabine—kidney cancer	0.000141	0.000671	CcSEcCtD
Rivaroxaban—Anaphylactic shock—Gemcitabine—kidney cancer	0.000141	0.000667	CcSEcCtD
Rivaroxaban—Oedema—Gemcitabine—kidney cancer	0.000141	0.000667	CcSEcCtD
Rivaroxaban—Infection—Gemcitabine—kidney cancer	0.00014	0.000663	CcSEcCtD
Rivaroxaban—Back pain—Paclitaxel—kidney cancer	0.00014	0.000662	CcSEcCtD
Rivaroxaban—Dizziness—Vinblastine—kidney cancer	0.000139	0.000661	CcSEcCtD
Rivaroxaban—Dizziness—Everolimus—kidney cancer	0.000139	0.000658	CcSEcCtD
Rivaroxaban—Muscle spasms—Paclitaxel—kidney cancer	0.000139	0.000658	CcSEcCtD
Rivaroxaban—Abdominal pain—Sunitinib—kidney cancer	0.000139	0.000657	CcSEcCtD
Rivaroxaban—Diarrhoea—Erlotinib—kidney cancer	0.000139	0.000657	CcSEcCtD
Rivaroxaban—Hypotension—Vincristine—kidney cancer	0.000139	0.000657	CcSEcCtD
Rivaroxaban—Nervous system disorder—Gemcitabine—kidney cancer	0.000138	0.000654	CcSEcCtD
Rivaroxaban—Renal failure acute—Doxorubicin—kidney cancer	0.000137	0.000651	CcSEcCtD
Rivaroxaban—Feeling abnormal—Dactinomycin—kidney cancer	0.000137	0.000649	CcSEcCtD
Rivaroxaban—Haemoglobin—Capecitabine—kidney cancer	0.000137	0.000649	CcSEcCtD
Rivaroxaban—Skin disorder—Gemcitabine—kidney cancer	0.000137	0.000648	CcSEcCtD
Rivaroxaban—Haemorrhage—Capecitabine—kidney cancer	0.000136	0.000645	CcSEcCtD
Rivaroxaban—Hepatitis—Capecitabine—kidney cancer	0.000136	0.000645	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Dactinomycin—kidney cancer	0.000136	0.000644	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Capecitabine—kidney cancer	0.000134	0.000637	CcSEcCtD
Rivaroxaban—Hypersensitivity—Sorafenib—kidney cancer	0.000134	0.000637	CcSEcCtD
Rivaroxaban—Vomiting—Vinblastine—kidney cancer	0.000134	0.000635	CcSEcCtD
Rivaroxaban—Dizziness—Erlotinib—kidney cancer	0.000134	0.000635	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Paclitaxel—kidney cancer	0.000134	0.000635	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Capecitabine—kidney cancer	0.000134	0.000634	CcSEcCtD
Rivaroxaban—Vomiting—Everolimus—kidney cancer	0.000134	0.000633	CcSEcCtD
Rivaroxaban—Anaemia—Paclitaxel—kidney cancer	0.000133	0.000633	CcSEcCtD
Rivaroxaban—Urethral disorder—Capecitabine—kidney cancer	0.000133	0.000633	CcSEcCtD
Rivaroxaban—Dermatitis bullous—Doxorubicin—kidney cancer	0.000133	0.000629	CcSEcCtD
Rivaroxaban—Rash—Everolimus—kidney cancer	0.000132	0.000628	CcSEcCtD
Rivaroxaban—Dermatitis—Everolimus—kidney cancer	0.000132	0.000627	CcSEcCtD
Rivaroxaban—Headache—Vinblastine—kidney cancer	0.000132	0.000626	CcSEcCtD
Rivaroxaban—Angioedema—Paclitaxel—kidney cancer	0.000132	0.000625	CcSEcCtD
Rivaroxaban—Headache—Everolimus—kidney cancer	0.000132	0.000624	CcSEcCtD
Rivaroxaban—Hypotension—Gemcitabine—kidney cancer	0.000131	0.000624	CcSEcCtD
Rivaroxaban—Abdominal pain—Dactinomycin—kidney cancer	0.000131	0.000622	CcSEcCtD
Rivaroxaban—Asthenia—Sorafenib—kidney cancer	0.000131	0.00062	CcSEcCtD
Rivaroxaban—Malaise—Paclitaxel—kidney cancer	0.00013	0.000617	CcSEcCtD
Rivaroxaban—Syncope—Paclitaxel—kidney cancer	0.000129	0.000614	CcSEcCtD
Rivaroxaban—Hypersensitivity—Sunitinib—kidney cancer	0.000129	0.000613	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—ALDH1A1—kidney cancer	0.000129	0.00385	CbGpPWpGaD
Rivaroxaban—Pruritus—Sorafenib—kidney cancer	0.000129	0.000611	CcSEcCtD
Rivaroxaban—Vomiting—Erlotinib—kidney cancer	0.000129	0.000611	CcSEcCtD
Rivaroxaban—Erythema multiforme—Capecitabine—kidney cancer	0.000129	0.00061	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Vincristine—kidney cancer	0.000128	0.000607	CcSEcCtD
Rivaroxaban—Fatigue—Vincristine—kidney cancer	0.000128	0.000606	CcSEcCtD
Rivaroxaban—Rash—Erlotinib—kidney cancer	0.000128	0.000606	CcSEcCtD
Rivaroxaban—Dermatitis—Erlotinib—kidney cancer	0.000128	0.000605	CcSEcCtD
Rivaroxaban—Eye disorder—Capecitabine—kidney cancer	0.000127	0.000603	CcSEcCtD
Rivaroxaban—Headache—Erlotinib—kidney cancer	0.000127	0.000602	CcSEcCtD
Rivaroxaban—Loss of consciousness—Paclitaxel—kidney cancer	0.000127	0.000602	CcSEcCtD
Rivaroxaban—Pain—Vincristine—kidney cancer	0.000127	0.000602	CcSEcCtD
Rivaroxaban—Constipation—Vincristine—kidney cancer	0.000127	0.000602	CcSEcCtD
Rivaroxaban—Osteoarthritis—Doxorubicin—kidney cancer	0.000127	0.000601	CcSEcCtD
Rivaroxaban—Pain in extremity—Doxorubicin—kidney cancer	0.000127	0.000601	CcSEcCtD
Rivaroxaban—Gastrointestinal haemorrhage—Doxorubicin—kidney cancer	0.000127	0.000601	CcSEcCtD
Rivaroxaban—Cardiac disorder—Capecitabine—kidney cancer	0.000126	0.000599	CcSEcCtD
Rivaroxaban—Asthenia—Sunitinib—kidney cancer	0.000126	0.000597	CcSEcCtD
Rivaroxaban—Dyspnoea—Gemcitabine—kidney cancer	0.000125	0.000595	CcSEcCtD
Rivaroxaban—Nausea—Vinblastine—kidney cancer	0.000125	0.000594	CcSEcCtD
Rivaroxaban—Nausea—Everolimus—kidney cancer	0.000125	0.000591	CcSEcCtD
Rivaroxaban—Diarrhoea—Sorafenib—kidney cancer	0.000125	0.000591	CcSEcCtD
Rivaroxaban—Pruritus—Sunitinib—kidney cancer	0.000124	0.000588	CcSEcCtD
Rivaroxaban—CYP3A4—Irinotecan Pathway—APC—kidney cancer	0.000124	0.0037	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—ITPR2—kidney cancer	0.000124	0.00369	CbGpPWpGaD
Rivaroxaban—Angiopathy—Capecitabine—kidney cancer	0.000123	0.000585	CcSEcCtD
Rivaroxaban—Immune system disorder—Capecitabine—kidney cancer	0.000123	0.000583	CcSEcCtD
Rivaroxaban—Chest pain—Paclitaxel—kidney cancer	0.000123	0.000583	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Capecitabine—kidney cancer	0.000123	0.000582	CcSEcCtD
Rivaroxaban—Hypersensitivity—Dactinomycin—kidney cancer	0.000122	0.00058	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000122	0.000579	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000121	0.000576	CcSEcCtD
Rivaroxaban—Discomfort—Paclitaxel—kidney cancer	0.000121	0.000576	CcSEcCtD
Rivaroxaban—Fatigue—Gemcitabine—kidney cancer	0.000121	0.000575	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Vincristine—kidney cancer	0.000121	0.000575	CcSEcCtD
Rivaroxaban—Dizziness—Sorafenib—kidney cancer	0.000121	0.000572	CcSEcCtD
Rivaroxaban—Constipation—Gemcitabine—kidney cancer	0.00012	0.000571	CcSEcCtD
Rivaroxaban—Pain—Gemcitabine—kidney cancer	0.00012	0.000571	CcSEcCtD
Rivaroxaban—Nausea—Erlotinib—kidney cancer	0.00012	0.000571	CcSEcCtD
Rivaroxaban—Dry mouth—Paclitaxel—kidney cancer	0.00012	0.00057	CcSEcCtD
Rivaroxaban—Diarrhoea—Sunitinib—kidney cancer	0.00012	0.000569	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	0.000119	0.00355	CbGpPWpGaD
Rivaroxaban—Asthenia—Dactinomycin—kidney cancer	0.000119	0.000565	CcSEcCtD
Rivaroxaban—CYP3A4—Xenobiotics—CYP1A1—kidney cancer	0.000119	0.00355	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PDHB—kidney cancer	0.000119	0.00354	CbGpPWpGaD
Rivaroxaban—Blood creatinine increased—Doxorubicin—kidney cancer	0.000119	0.000563	CcSEcCtD
Rivaroxaban—CYP2J2—Biological oxidations—POMC—kidney cancer	0.000118	0.00353	CbGpPWpGaD
Rivaroxaban—Anaphylactic shock—Paclitaxel—kidney cancer	0.000118	0.000559	CcSEcCtD
Rivaroxaban—Oedema—Paclitaxel—kidney cancer	0.000118	0.000559	CcSEcCtD
Rivaroxaban—Abdominal pain—Vincristine—kidney cancer	0.000117	0.000556	CcSEcCtD
Rivaroxaban—Infection—Paclitaxel—kidney cancer	0.000117	0.000555	CcSEcCtD
Rivaroxaban—Dizziness—Sunitinib—kidney cancer	0.000116	0.00055	CcSEcCtD
Rivaroxaban—Feeling abnormal—Gemcitabine—kidney cancer	0.000116	0.00055	CcSEcCtD
Rivaroxaban—Shock—Paclitaxel—kidney cancer	0.000116	0.00055	CcSEcCtD
Rivaroxaban—Vomiting—Sorafenib—kidney cancer	0.000116	0.00055	CcSEcCtD
Rivaroxaban—Abdominal pain upper—Doxorubicin—kidney cancer	0.000116	0.000549	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—MME—kidney cancer	0.000116	0.00345	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Paclitaxel—kidney cancer	0.000116	0.000548	CcSEcCtD
Rivaroxaban—Tachycardia—Paclitaxel—kidney cancer	0.000115	0.000545	CcSEcCtD
Rivaroxaban—Rash—Sorafenib—kidney cancer	0.000115	0.000545	CcSEcCtD
Rivaroxaban—Dermatitis—Sorafenib—kidney cancer	0.000115	0.000544	CcSEcCtD
Rivaroxaban—Back pain—Capecitabine—kidney cancer	0.000115	0.000543	CcSEcCtD
Rivaroxaban—CYP3A4—Tamoxifen metabolism—CYP1A1—kidney cancer	0.000114	0.00341	CbGpPWpGaD
Rivaroxaban—Skin disorder—Paclitaxel—kidney cancer	0.000114	0.000543	CcSEcCtD
Rivaroxaban—Headache—Sorafenib—kidney cancer	0.000114	0.000541	CcSEcCtD
Rivaroxaban—Muscle spasms—Capecitabine—kidney cancer	0.000114	0.00054	CcSEcCtD
Rivaroxaban—Diarrhoea—Dactinomycin—kidney cancer	0.000114	0.000539	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—ALDH1A1—kidney cancer	0.000113	0.00337	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CCBL1—kidney cancer	0.000112	0.00333	CbGpPWpGaD
Rivaroxaban—Vomiting—Sunitinib—kidney cancer	0.000112	0.000529	CcSEcCtD
Rivaroxaban—Rash—Sunitinib—kidney cancer	0.000111	0.000524	CcSEcCtD
Rivaroxaban—Dermatitis—Sunitinib—kidney cancer	0.00011	0.000524	CcSEcCtD
Rivaroxaban—Hypotension—Paclitaxel—kidney cancer	0.00011	0.000522	CcSEcCtD
Rivaroxaban—Ill-defined disorder—Capecitabine—kidney cancer	0.00011	0.000521	CcSEcCtD
Rivaroxaban—Headache—Sunitinib—kidney cancer	0.00011	0.000521	CcSEcCtD
Rivaroxaban—Anaemia—Capecitabine—kidney cancer	0.000109	0.000519	CcSEcCtD
Rivaroxaban—CYP3A4—Biological oxidations—ACY1—kidney cancer	0.000109	0.00326	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Vincristine—kidney cancer	0.000109	0.000518	CcSEcCtD
Rivaroxaban—ABCB1—Allograft Rejection—IL13—kidney cancer	0.000109	0.00324	CbGpPWpGaD
Rivaroxaban—Nausea—Sorafenib—kidney cancer	0.000108	0.000513	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—RPL14—kidney cancer	0.000108	0.00321	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—HSPD1—kidney cancer	0.000108	0.00321	CbGpPWpGaD
Rivaroxaban—Malaise—Capecitabine—kidney cancer	0.000107	0.000507	CcSEcCtD
Rivaroxaban—Angina pectoris—Doxorubicin—kidney cancer	0.000107	0.000506	CcSEcCtD
Rivaroxaban—Asthenia—Vincristine—kidney cancer	0.000106	0.000505	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	0.000106	0.00317	CbGpPWpGaD
Rivaroxaban—Syncope—Capecitabine—kidney cancer	0.000106	0.000504	CcSEcCtD
Rivaroxaban—Vomiting—Dactinomycin—kidney cancer	0.000106	0.000501	CcSEcCtD
Rivaroxaban—Dyspnoea—Paclitaxel—kidney cancer	0.000105	0.000498	CcSEcCtD
Rivaroxaban—CYP3A5—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	0.000105	0.00313	CbGpPWpGaD
Rivaroxaban—Rash—Dactinomycin—kidney cancer	0.000105	0.000496	CcSEcCtD
Rivaroxaban—Nausea—Sunitinib—kidney cancer	0.000104	0.000494	CcSEcCtD
Rivaroxaban—Loss of consciousness—Capecitabine—kidney cancer	0.000104	0.000494	CcSEcCtD
Rivaroxaban—Dyspepsia—Paclitaxel—kidney cancer	0.000104	0.000492	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—SLC2A1—kidney cancer	0.000102	0.00305	CbGpPWpGaD
Rivaroxaban—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000102	0.000482	CcSEcCtD
Rivaroxaban—Fatigue—Paclitaxel—kidney cancer	0.000102	0.000482	CcSEcCtD
Rivaroxaban—Diarrhoea—Vincristine—kidney cancer	0.000101	0.000481	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	0.000101	0.00301	CbGpPWpGaD
Rivaroxaban—Asthenia—Gemcitabine—kidney cancer	0.000101	0.000479	CcSEcCtD
Rivaroxaban—Chest pain—Capecitabine—kidney cancer	0.000101	0.000478	CcSEcCtD
Rivaroxaban—Pain—Paclitaxel—kidney cancer	0.000101	0.000478	CcSEcCtD
Rivaroxaban—Constipation—Paclitaxel—kidney cancer	0.000101	0.000478	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.0001	0.000475	CcSEcCtD
Rivaroxaban—Discomfort—Capecitabine—kidney cancer	9.97e-05	0.000473	CcSEcCtD
Rivaroxaban—Pruritus—Gemcitabine—kidney cancer	9.96e-05	0.000472	CcSEcCtD
Rivaroxaban—Dry mouth—Capecitabine—kidney cancer	9.86e-05	0.000468	CcSEcCtD
Rivaroxaban—Nausea—Dactinomycin—kidney cancer	9.86e-05	0.000468	CcSEcCtD
Rivaroxaban—Dizziness—Vincristine—kidney cancer	9.81e-05	0.000465	CcSEcCtD
Rivaroxaban—Infestation—Doxorubicin—kidney cancer	9.77e-05	0.000463	CcSEcCtD
Rivaroxaban—Infestation NOS—Doxorubicin—kidney cancer	9.77e-05	0.000463	CcSEcCtD
Rivaroxaban—Feeling abnormal—Paclitaxel—kidney cancer	9.71e-05	0.00046	CcSEcCtD
Rivaroxaban—Stevens-Johnson syndrome—Doxorubicin—kidney cancer	9.69e-05	0.000459	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—PPAT—kidney cancer	9.69e-05	0.00289	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GLIPR1—kidney cancer	9.69e-05	0.00289	CbGpPWpGaD
Rivaroxaban—Oedema—Capecitabine—kidney cancer	9.67e-05	0.000458	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Paclitaxel—kidney cancer	9.63e-05	0.000457	CcSEcCtD
Rivaroxaban—Diarrhoea—Gemcitabine—kidney cancer	9.63e-05	0.000457	CcSEcCtD
Rivaroxaban—Renal failure—Doxorubicin—kidney cancer	9.61e-05	0.000456	CcSEcCtD
Rivaroxaban—Infection—Capecitabine—kidney cancer	9.61e-05	0.000455	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	9.56e-05	0.00285	CbGpPWpGaD
Rivaroxaban—Jaundice—Doxorubicin—kidney cancer	9.53e-05	0.000452	CcSEcCtD
Rivaroxaban—Shock—Capecitabine—kidney cancer	9.51e-05	0.000451	CcSEcCtD
Rivaroxaban—Urinary tract infection—Doxorubicin—kidney cancer	9.5e-05	0.00045	CcSEcCtD
Rivaroxaban—Nervous system disorder—Capecitabine—kidney cancer	9.48e-05	0.00045	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	9.47e-05	0.00282	CbGpPWpGaD
Rivaroxaban—Tachycardia—Capecitabine—kidney cancer	9.44e-05	0.000447	CcSEcCtD
Rivaroxaban—Vomiting—Vincristine—kidney cancer	9.43e-05	0.000447	CcSEcCtD
Rivaroxaban—Skin disorder—Capecitabine—kidney cancer	9.39e-05	0.000445	CcSEcCtD
Rivaroxaban—Urticaria—Paclitaxel—kidney cancer	9.36e-05	0.000444	CcSEcCtD
Rivaroxaban—Rash—Vincristine—kidney cancer	9.35e-05	0.000444	CcSEcCtD
Rivaroxaban—Dermatitis—Vincristine—kidney cancer	9.34e-05	0.000443	CcSEcCtD
Rivaroxaban—Haematuria—Doxorubicin—kidney cancer	9.32e-05	0.000442	CcSEcCtD
Rivaroxaban—Abdominal pain—Paclitaxel—kidney cancer	9.31e-05	0.000442	CcSEcCtD
Rivaroxaban—Headache—Vincristine—kidney cancer	9.29e-05	0.000441	CcSEcCtD
Rivaroxaban—Hepatobiliary disease—Doxorubicin—kidney cancer	9.24e-05	0.000438	CcSEcCtD
Rivaroxaban—Epistaxis—Doxorubicin—kidney cancer	9.22e-05	0.000437	CcSEcCtD
Rivaroxaban—Sinusitis—Doxorubicin—kidney cancer	9.17e-05	0.000435	CcSEcCtD
Rivaroxaban—Agranulocytosis—Doxorubicin—kidney cancer	9.12e-05	0.000432	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IFNA1—kidney cancer	9.07e-05	0.00271	CbGpPWpGaD
Rivaroxaban—Hypotension—Capecitabine—kidney cancer	9.03e-05	0.000428	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—APRT—kidney cancer	9.01e-05	0.00268	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—FH—kidney cancer	9.01e-05	0.00268	CbGpPWpGaD
Rivaroxaban—Vomiting—Gemcitabine—kidney cancer	8.95e-05	0.000424	CcSEcCtD
Rivaroxaban—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—kidney cancer	8.88e-05	0.00265	CbGpPWpGaD
Rivaroxaban—Rash—Gemcitabine—kidney cancer	8.87e-05	0.000421	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—ACHE—kidney cancer	8.87e-05	0.00264	CbGpPWpGaD
Rivaroxaban—Dermatitis—Gemcitabine—kidney cancer	8.86e-05	0.00042	CcSEcCtD
Rivaroxaban—Haemoglobin—Doxorubicin—kidney cancer	8.82e-05	0.000418	CcSEcCtD
Rivaroxaban—Headache—Gemcitabine—kidney cancer	8.82e-05	0.000418	CcSEcCtD
Rivaroxaban—Nausea—Vincristine—kidney cancer	8.81e-05	0.000418	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	8.8e-05	0.00262	CbGpPWpGaD
Rivaroxaban—Haemorrhage—Doxorubicin—kidney cancer	8.77e-05	0.000416	CcSEcCtD
Rivaroxaban—Hepatitis—Doxorubicin—kidney cancer	8.77e-05	0.000416	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—EIF4EBP1—kidney cancer	8.77e-05	0.00261	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Paclitaxel—kidney cancer	8.68e-05	0.000412	CcSEcCtD
Rivaroxaban—Urinary tract disorder—Doxorubicin—kidney cancer	8.66e-05	0.000411	CcSEcCtD
Rivaroxaban—Connective tissue disorder—Doxorubicin—kidney cancer	8.62e-05	0.000409	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	8.62e-05	0.00257	CbGpPWpGaD
Rivaroxaban—Dyspnoea—Capecitabine—kidney cancer	8.62e-05	0.000409	CcSEcCtD
Rivaroxaban—Urethral disorder—Doxorubicin—kidney cancer	8.6e-05	0.000408	CcSEcCtD
Rivaroxaban—Dyspepsia—Capecitabine—kidney cancer	8.51e-05	0.000404	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—GPC3—kidney cancer	8.47e-05	0.00252	CbGpPWpGaD
Rivaroxaban—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—kidney cancer	8.46e-05	0.00252	CbGpPWpGaD
Rivaroxaban—Asthenia—Paclitaxel—kidney cancer	8.45e-05	0.000401	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IFNA2—kidney cancer	8.44e-05	0.00252	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—PAX6—kidney cancer	8.44e-05	0.00252	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CTSD—kidney cancer	8.39e-05	0.0025	CbGpPWpGaD
Rivaroxaban—Nausea—Gemcitabine—kidney cancer	8.36e-05	0.000396	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Capecitabine—kidney cancer	8.35e-05	0.000396	CcSEcCtD
Rivaroxaban—Fatigue—Capecitabine—kidney cancer	8.34e-05	0.000395	CcSEcCtD
Rivaroxaban—Pruritus—Paclitaxel—kidney cancer	8.34e-05	0.000395	CcSEcCtD
Rivaroxaban—Erythema multiforme—Doxorubicin—kidney cancer	8.29e-05	0.000393	CcSEcCtD
Rivaroxaban—Constipation—Capecitabine—kidney cancer	8.27e-05	0.000392	CcSEcCtD
Rivaroxaban—Pain—Capecitabine—kidney cancer	8.27e-05	0.000392	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CA2—kidney cancer	8.24e-05	0.00246	CbGpPWpGaD
Rivaroxaban—Eye disorder—Doxorubicin—kidney cancer	8.2e-05	0.000389	CcSEcCtD
Rivaroxaban—Cardiac disorder—Doxorubicin—kidney cancer	8.14e-05	0.000386	CcSEcCtD
Rivaroxaban—Diarrhoea—Paclitaxel—kidney cancer	8.06e-05	0.000382	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ALAD—kidney cancer	8.03e-05	0.00239	CbGpPWpGaD
Rivaroxaban—Feeling abnormal—Capecitabine—kidney cancer	7.97e-05	0.000378	CcSEcCtD
Rivaroxaban—Angiopathy—Doxorubicin—kidney cancer	7.96e-05	0.000377	CcSEcCtD
Rivaroxaban—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	7.93e-05	0.00236	CbGpPWpGaD
Rivaroxaban—Immune system disorder—Doxorubicin—kidney cancer	7.92e-05	0.000376	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Capecitabine—kidney cancer	7.91e-05	0.000375	CcSEcCtD
Rivaroxaban—Mediastinal disorder—Doxorubicin—kidney cancer	7.91e-05	0.000375	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ST3GAL2—kidney cancer	7.83e-05	0.00234	CbGpPWpGaD
Rivaroxaban—CYP3A5—nephron tubule—kidney cancer	7.82e-05	0.0552	CbGeAlD
Rivaroxaban—Dizziness—Paclitaxel—kidney cancer	7.79e-05	0.000369	CcSEcCtD
Rivaroxaban—F10—Metabolism of proteins—BCHE—kidney cancer	7.73e-05	0.0023	CbGpPWpGaD
Rivaroxaban—Urticaria—Capecitabine—kidney cancer	7.68e-05	0.000364	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—ALDH1A1—kidney cancer	7.66e-05	0.00228	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Capecitabine—kidney cancer	7.64e-05	0.000362	CcSEcCtD
Rivaroxaban—F10—Hemostasis—IGF2—kidney cancer	7.6e-05	0.00227	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTT1—kidney cancer	7.58e-05	0.00226	CbGpPWpGaD
Rivaroxaban—Vomiting—Paclitaxel—kidney cancer	7.49e-05	0.000355	CcSEcCtD
Rivaroxaban—Rash—Paclitaxel—kidney cancer	7.43e-05	0.000352	CcSEcCtD
Rivaroxaban—Dermatitis—Paclitaxel—kidney cancer	7.42e-05	0.000352	CcSEcCtD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—kidney cancer	7.39e-05	0.0022	CbGpPWpGaD
Rivaroxaban—Back pain—Doxorubicin—kidney cancer	7.39e-05	0.00035	CcSEcCtD
Rivaroxaban—Headache—Paclitaxel—kidney cancer	7.38e-05	0.00035	CcSEcCtD
Rivaroxaban—Muscle spasms—Doxorubicin—kidney cancer	7.34e-05	0.000348	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—SLC5A3—kidney cancer	7.34e-05	0.00219	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PGK1—kidney cancer	7.34e-05	0.00219	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—LDHB—kidney cancer	7.2e-05	0.00215	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Capecitabine—kidney cancer	7.12e-05	0.000338	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—PTGS1—kidney cancer	7.11e-05	0.00212	CbGpPWpGaD
Rivaroxaban—CYP3A5—renal system—kidney cancer	7.1e-05	0.0502	CbGeAlD
Rivaroxaban—Ill-defined disorder—Doxorubicin—kidney cancer	7.09e-05	0.000336	CcSEcCtD
Rivaroxaban—Anaemia—Doxorubicin—kidney cancer	7.06e-05	0.000335	CcSEcCtD
Rivaroxaban—Nausea—Paclitaxel—kidney cancer	7e-05	0.000332	CcSEcCtD
Rivaroxaban—Asthenia—Capecitabine—kidney cancer	6.94e-05	0.000329	CcSEcCtD
Rivaroxaban—Malaise—Doxorubicin—kidney cancer	6.89e-05	0.000327	CcSEcCtD
Rivaroxaban—CYP3A5—kidney—kidney cancer	6.87e-05	0.0485	CbGeAlD
Rivaroxaban—Syncope—Doxorubicin—kidney cancer	6.85e-05	0.000325	CcSEcCtD
Rivaroxaban—Pruritus—Capecitabine—kidney cancer	6.84e-05	0.000324	CcSEcCtD
Rivaroxaban—Loss of consciousness—Doxorubicin—kidney cancer	6.71e-05	0.000318	CcSEcCtD
Rivaroxaban—CYP3A5—cortex of kidney—kidney cancer	6.69e-05	0.0472	CbGeAlD
Rivaroxaban—Diarrhoea—Capecitabine—kidney cancer	6.62e-05	0.000314	CcSEcCtD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—HIF1A—kidney cancer	6.61e-05	0.00197	CbGpPWpGaD
Rivaroxaban—Chest pain—Doxorubicin—kidney cancer	6.5e-05	0.000308	CcSEcCtD
Rivaroxaban—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	6.46e-05	0.000306	CcSEcCtD
Rivaroxaban—CYP3A5—Phase 1 - Functionalization of compounds—POMC—kidney cancer	6.43e-05	0.00192	CbGpPWpGaD
Rivaroxaban—Discomfort—Doxorubicin—kidney cancer	6.42e-05	0.000305	CcSEcCtD
Rivaroxaban—Dizziness—Capecitabine—kidney cancer	6.39e-05	0.000303	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—JUND—kidney cancer	6.38e-05	0.0019	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—APAF1—kidney cancer	6.38e-05	0.0019	CbGpPWpGaD
Rivaroxaban—Dry mouth—Doxorubicin—kidney cancer	6.36e-05	0.000302	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—CA9—kidney cancer	6.24e-05	0.00186	CbGpPWpGaD
Rivaroxaban—Anaphylactic shock—Doxorubicin—kidney cancer	6.23e-05	0.000296	CcSEcCtD
Rivaroxaban—Oedema—Doxorubicin—kidney cancer	6.23e-05	0.000296	CcSEcCtD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—kidney cancer	6.22e-05	0.00185	CbGpPWpGaD
Rivaroxaban—Infection—Doxorubicin—kidney cancer	6.19e-05	0.000294	CcSEcCtD
Rivaroxaban—Vomiting—Capecitabine—kidney cancer	6.15e-05	0.000292	CcSEcCtD
Rivaroxaban—Shock—Doxorubicin—kidney cancer	6.13e-05	0.000291	CcSEcCtD
Rivaroxaban—CYP3A4—Tryptophan metabolism—CYP1A1—kidney cancer	6.11e-05	0.00182	CbGpPWpGaD
Rivaroxaban—Nervous system disorder—Doxorubicin—kidney cancer	6.11e-05	0.00029	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	6.1e-05	0.00182	CbGpPWpGaD
Rivaroxaban—Rash—Capecitabine—kidney cancer	6.1e-05	0.000289	CcSEcCtD
Rivaroxaban—Dermatitis—Capecitabine—kidney cancer	6.09e-05	0.000289	CcSEcCtD
Rivaroxaban—Tachycardia—Doxorubicin—kidney cancer	6.08e-05	0.000288	CcSEcCtD
Rivaroxaban—Headache—Capecitabine—kidney cancer	6.06e-05	0.000287	CcSEcCtD
Rivaroxaban—Skin disorder—Doxorubicin—kidney cancer	6.05e-05	0.000287	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—kidney cancer	6.05e-05	0.0018	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—ALDH1A1—kidney cancer	6e-05	0.00179	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—IGF2—kidney cancer	5.98e-05	0.00178	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—RYR1—kidney cancer	5.94e-05	0.00177	CbGpPWpGaD
Rivaroxaban—Hypotension—Doxorubicin—kidney cancer	5.82e-05	0.000276	CcSEcCtD
Rivaroxaban—Nausea—Capecitabine—kidney cancer	5.74e-05	0.000272	CcSEcCtD
Rivaroxaban—Dyspnoea—Doxorubicin—kidney cancer	5.56e-05	0.000263	CcSEcCtD
Rivaroxaban—Dyspepsia—Doxorubicin—kidney cancer	5.49e-05	0.00026	CcSEcCtD
Rivaroxaban—Gastrointestinal disorder—Doxorubicin—kidney cancer	5.38e-05	0.000255	CcSEcCtD
Rivaroxaban—Fatigue—Doxorubicin—kidney cancer	5.37e-05	0.000255	CcSEcCtD
Rivaroxaban—CYP3A4—renal system—kidney cancer	5.33e-05	0.0376	CbGeAlD
Rivaroxaban—Constipation—Doxorubicin—kidney cancer	5.33e-05	0.000253	CcSEcCtD
Rivaroxaban—Pain—Doxorubicin—kidney cancer	5.33e-05	0.000253	CcSEcCtD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—kidney cancer	5.31e-05	0.00158	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CRABP1—kidney cancer	5.31e-05	0.00158	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ACHE—kidney cancer	5.26e-05	0.00157	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTP1—kidney cancer	5.26e-05	0.00157	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTP1—kidney cancer	5.18e-05	0.00155	CbGpPWpGaD
Rivaroxaban—CYP3A4—kidney—kidney cancer	5.15e-05	0.0364	CbGeAlD
Rivaroxaban—Feeling abnormal—Doxorubicin—kidney cancer	5.14e-05	0.000244	CcSEcCtD
Rivaroxaban—Gastrointestinal pain—Doxorubicin—kidney cancer	5.1e-05	0.000242	CcSEcCtD
Rivaroxaban—Urticaria—Doxorubicin—kidney cancer	4.95e-05	0.000235	CcSEcCtD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—kidney cancer	4.94e-05	0.00147	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ITPR2—kidney cancer	4.93e-05	0.00147	CbGpPWpGaD
Rivaroxaban—Abdominal pain—Doxorubicin—kidney cancer	4.93e-05	0.000234	CcSEcCtD
Rivaroxaban—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—kidney cancer	4.88e-05	0.00145	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—kidney cancer	4.84e-05	0.00144	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—GSTM1—kidney cancer	4.83e-05	0.00144	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—GSTM1—kidney cancer	4.76e-05	0.00142	CbGpPWpGaD
Rivaroxaban—Hypersensitivity—Doxorubicin—kidney cancer	4.59e-05	0.000218	CcSEcCtD
Rivaroxaban—CYP3A5—Biological oxidations—CYP1A1—kidney cancer	4.58e-05	0.00137	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—POMC—kidney cancer	4.55e-05	0.00136	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metapathway biotransformation—CYP1A1—kidney cancer	4.52e-05	0.00135	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ACHE—kidney cancer	4.5e-05	0.00134	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTT1—kidney cancer	4.5e-05	0.00134	CbGpPWpGaD
Rivaroxaban—Asthenia—Doxorubicin—kidney cancer	4.47e-05	0.000212	CcSEcCtD
Rivaroxaban—Pruritus—Doxorubicin—kidney cancer	4.41e-05	0.000209	CcSEcCtD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—JUNB—kidney cancer	4.34e-05	0.00129	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PAK1—kidney cancer	4.34e-05	0.00129	CbGpPWpGaD
Rivaroxaban—Diarrhoea—Doxorubicin—kidney cancer	4.26e-05	0.000202	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—SCARB1—kidney cancer	4.26e-05	0.00127	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS1—kidney cancer	4.22e-05	0.00126	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—RAF1—kidney cancer	4.18e-05	0.00125	CbGpPWpGaD
Rivaroxaban—ABCB1—nephron tubule—kidney cancer	4.15e-05	0.0293	CbGeAlD
Rivaroxaban—CYP2J2—Metabolism—PSMD7—kidney cancer	4.13e-05	0.00123	CbGpPWpGaD
Rivaroxaban—Dizziness—Doxorubicin—kidney cancer	4.12e-05	0.000195	CcSEcCtD
Rivaroxaban—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—kidney cancer	4.07e-05	0.00121	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—EGR1—kidney cancer	4.06e-05	0.00121	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ACY1—kidney cancer	4.03e-05	0.0012	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—kidney cancer	4.01e-05	0.00119	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—POMC—kidney cancer	3.99e-05	0.00119	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—JUN—kidney cancer	3.99e-05	0.00119	CbGpPWpGaD
Rivaroxaban—Vomiting—Doxorubicin—kidney cancer	3.96e-05	0.000188	CcSEcCtD
Rivaroxaban—Rash—Doxorubicin—kidney cancer	3.93e-05	0.000186	CcSEcCtD
Rivaroxaban—Dermatitis—Doxorubicin—kidney cancer	3.93e-05	0.000186	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—BCHE—kidney cancer	3.92e-05	0.00117	CbGpPWpGaD
Rivaroxaban—Headache—Doxorubicin—kidney cancer	3.9e-05	0.000185	CcSEcCtD
Rivaroxaban—CYP2J2—Metabolism—SLC5A5—kidney cancer	3.87e-05	0.00115	CbGpPWpGaD
Rivaroxaban—ABCB1—renal system—kidney cancer	3.77e-05	0.0267	CbGeAlD
Rivaroxaban—F10—Hemostasis—IL2—kidney cancer	3.75e-05	0.00112	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—SLC2A1—kidney cancer	3.74e-05	0.00111	CbGpPWpGaD
Rivaroxaban—Nausea—Doxorubicin—kidney cancer	3.7e-05	0.000176	CcSEcCtD
Rivaroxaban—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—kidney cancer	3.69e-05	0.0011	CbGpPWpGaD
Rivaroxaban—ABCB1—kidney—kidney cancer	3.65e-05	0.0258	CbGeAlD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	3.63e-05	0.00108	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—kidney cancer	3.56e-05	0.00106	CbGpPWpGaD
Rivaroxaban—ABCB1—cortex of kidney—kidney cancer	3.55e-05	0.0251	CbGeAlD
Rivaroxaban—ABCB1—Allograft Rejection—IL2—kidney cancer	3.55e-05	0.00106	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—kidney cancer	3.53e-05	0.00105	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTT1—kidney cancer	3.53e-05	0.00105	CbGpPWpGaD
Rivaroxaban—ABCB1—HIF-1-alpha transcription factor network—VEGFA—kidney cancer	3.48e-05	0.00104	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PDHB—kidney cancer	3.42e-05	0.00102	CbGpPWpGaD
Rivaroxaban—CYP3A5—Biological oxidations—POMC—kidney cancer	3.41e-05	0.00102	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ATP7B—kidney cancer	3.41e-05	0.00102	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—ANXA2—kidney cancer	3.41e-05	0.00102	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC5A3—kidney cancer	3.41e-05	0.00102	CbGpPWpGaD
Rivaroxaban—ABCB1—gonad—kidney cancer	3.38e-05	0.0239	CbGeAlD
Rivaroxaban—CYP3A4—Biological oxidations—PTGS1—kidney cancer	3.3e-05	0.000985	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CCBL1—kidney cancer	3.22e-05	0.00096	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—VEGFA—kidney cancer	3.19e-05	0.000951	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	3.16e-05	0.000943	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTP1—kidney cancer	3.12e-05	0.00093	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ACY1—kidney cancer	3.04e-05	0.000906	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MAPK3—kidney cancer	3.02e-05	0.000899	CbGpPWpGaD
Rivaroxaban—ABCB1—Allograft Rejection—VEGFA—kidney cancer	3.02e-05	0.000899	CbGpPWpGaD
Rivaroxaban—CYP3A4—Phase 1 - Functionalization of compounds—POMC—kidney cancer	2.99e-05	0.000891	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—ABCB1—kidney cancer	2.95e-05	0.00088	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—MAPK1—kidney cancer	2.87e-05	0.000856	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—GSTM1—kidney cancer	2.87e-05	0.000854	CbGpPWpGaD
Rivaroxaban—F10—Metabolism of proteins—CTNNB1—kidney cancer	2.85e-05	0.000849	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PPAT—kidney cancer	2.79e-05	0.000832	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GLIPR1—kidney cancer	2.79e-05	0.000832	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—CYP1A1—kidney cancer	2.72e-05	0.00081	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—KRAS—kidney cancer	2.71e-05	0.000808	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—FH—kidney cancer	2.6e-05	0.000774	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—APRT—kidney cancer	2.6e-05	0.000774	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PDHB—kidney cancer	2.58e-05	0.00077	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—PIK3CA—kidney cancer	2.49e-05	0.000743	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—APC—kidney cancer	2.49e-05	0.000742	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTP1—kidney cancer	2.44e-05	0.000729	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GPC3—kidney cancer	2.44e-05	0.000728	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CCBL1—kidney cancer	2.43e-05	0.000724	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTP1—kidney cancer	2.41e-05	0.000719	CbGpPWpGaD
Rivaroxaban—F10—Hemostasis—TP53—kidney cancer	2.41e-05	0.000718	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CA2—kidney cancer	2.37e-05	0.000708	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALAD—kidney cancer	2.31e-05	0.00069	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ST3GAL2—kidney cancer	2.26e-05	0.000673	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—GSTM1—kidney cancer	2.25e-05	0.000669	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	2.23e-05	0.000665	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—GSTM1—kidney cancer	2.21e-05	0.00066	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ALDH1A1—kidney cancer	2.21e-05	0.000658	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—CYP1A1—kidney cancer	2.13e-05	0.000635	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PGK1—kidney cancer	2.12e-05	0.000631	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC5A3—kidney cancer	2.12e-05	0.000631	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PPAT—kidney cancer	2.11e-05	0.000628	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GLIPR1—kidney cancer	2.11e-05	0.000628	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metapathway biotransformation—CYP1A1—kidney cancer	2.1e-05	0.000626	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—LDHB—kidney cancer	2.07e-05	0.000619	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—POMC—kidney cancer	2.03e-05	0.000604	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—FH—kidney cancer	1.96e-05	0.000584	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—APRT—kidney cancer	1.96e-05	0.000584	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—kidney cancer	1.95e-05	0.000582	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—kidney cancer	1.93e-05	0.000576	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—kidney cancer	1.89e-05	0.000563	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ACY1—kidney cancer	1.87e-05	0.000558	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GPC3—kidney cancer	1.84e-05	0.000549	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CA9—kidney cancer	1.8e-05	0.000536	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC5A5—kidney cancer	1.8e-05	0.000536	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CA2—kidney cancer	1.79e-05	0.000534	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—kidney cancer	1.79e-05	0.000534	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALAD—kidney cancer	1.75e-05	0.00052	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—SLC2A1—kidney cancer	1.74e-05	0.000518	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—kidney cancer	1.71e-05	0.000509	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ST3GAL2—kidney cancer	1.7e-05	0.000508	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—kidney cancer	1.7e-05	0.000508	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—kidney cancer	1.69e-05	0.000504	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ALDH1A1—kidney cancer	1.67e-05	0.000496	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—kidney cancer	1.65e-05	0.000491	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTGS2—kidney cancer	1.62e-05	0.000482	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PGK1—kidney cancer	1.6e-05	0.000476	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC5A3—kidney cancer	1.6e-05	0.000476	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PDHB—kidney cancer	1.59e-05	0.000475	CbGpPWpGaD
Rivaroxaban—CYP3A4—Biological oxidations—POMC—kidney cancer	1.59e-05	0.000473	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—LDHB—kidney cancer	1.57e-05	0.000467	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CRABP1—kidney cancer	1.53e-05	0.000456	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CCBL1—kidney cancer	1.5e-05	0.000446	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—kidney cancer	1.49e-05	0.000444	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ITPR2—kidney cancer	1.42e-05	0.000424	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PTEN—kidney cancer	1.41e-05	0.00042	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—kidney cancer	1.41e-05	0.00042	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—kidney cancer	1.37e-05	0.000408	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CA9—kidney cancer	1.36e-05	0.000405	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—kidney cancer	1.34e-05	0.000399	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GLIPR1—kidney cancer	1.3e-05	0.000387	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PPAT—kidney cancer	1.3e-05	0.000387	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTT1—kidney cancer	1.3e-05	0.000387	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ACHE—kidney cancer	1.3e-05	0.000387	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—kidney cancer	1.27e-05	0.000377	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SCARB1—kidney cancer	1.23e-05	0.000366	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS1—kidney cancer	1.22e-05	0.000362	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—APRT—kidney cancer	1.21e-05	0.00036	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—FH—kidney cancer	1.21e-05	0.00036	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PSMD7—kidney cancer	1.19e-05	0.000355	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—kidney cancer	1.16e-05	0.000347	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CRABP1—kidney cancer	1.15e-05	0.000344	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GPC3—kidney cancer	1.13e-05	0.000338	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—BCHE—kidney cancer	1.13e-05	0.000337	CbGpPWpGaD
Rivaroxaban—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—kidney cancer	1.12e-05	0.000335	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC5A5—kidney cancer	1.12e-05	0.000333	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CA2—kidney cancer	1.1e-05	0.000329	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—SLC2A1—kidney cancer	1.08e-05	0.000321	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALAD—kidney cancer	1.08e-05	0.000321	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ITPR2—kidney cancer	1.07e-05	0.00032	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ST3GAL2—kidney cancer	1.05e-05	0.000313	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ALDH1A1—kidney cancer	1.03e-05	0.000306	CbGpPWpGaD
Rivaroxaban—CYP2J2—Metabolism—PIK3CA—kidney cancer	9.94e-06	0.000296	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC5A3—kidney cancer	9.84e-06	0.000293	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PGK1—kidney cancer	9.84e-06	0.000293	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—ACHE—kidney cancer	9.79e-06	0.000292	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTT1—kidney cancer	9.79e-06	0.000292	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—LDHB—kidney cancer	9.65e-06	0.000288	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SCARB1—kidney cancer	9.26e-06	0.000276	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS1—kidney cancer	9.17e-06	0.000273	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PSMD7—kidney cancer	8.99e-06	0.000268	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTP1—kidney cancer	8.99e-06	0.000268	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—BCHE—kidney cancer	8.52e-06	0.000254	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—ABCB1—kidney cancer	8.51e-06	0.000254	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC5A5—kidney cancer	8.42e-06	0.000251	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CA9—kidney cancer	8.36e-06	0.000249	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—GSTM1—kidney cancer	8.26e-06	0.000246	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—SLC2A1—kidney cancer	8.13e-06	0.000242	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—CYP1A1—kidney cancer	7.83e-06	0.000233	CbGpPWpGaD
Rivaroxaban—ABCB1—Transmembrane transport of small molecules—RAF1—kidney cancer	7.76e-06	0.000231	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CRABP1—kidney cancer	7.11e-06	0.000212	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTP1—kidney cancer	6.78e-06	0.000202	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ITPR2—kidney cancer	6.61e-06	0.000197	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—GSTM1—kidney cancer	6.23e-06	0.000186	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ACHE—kidney cancer	6.03e-06	0.00018	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTT1—kidney cancer	6.03e-06	0.00018	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—CYP1A1—kidney cancer	5.91e-06	0.000176	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—POMC—kidney cancer	5.84e-06	0.000174	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SCARB1—kidney cancer	5.71e-06	0.00017	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS1—kidney cancer	5.65e-06	0.000168	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PSMD7—kidney cancer	5.54e-06	0.000165	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—BCHE—kidney cancer	5.25e-06	0.000157	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC5A5—kidney cancer	5.19e-06	0.000155	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—SLC2A1—kidney cancer	5.01e-06	0.000149	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTGS2—kidney cancer	4.66e-06	0.000139	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—POMC—kidney cancer	4.41e-06	0.000131	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTP1—kidney cancer	4.18e-06	0.000125	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PTEN—kidney cancer	4.06e-06	0.000121	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—ABCB1—kidney cancer	3.96e-06	0.000118	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—GSTM1—kidney cancer	3.84e-06	0.000114	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—CYP1A1—kidney cancer	3.64e-06	0.000109	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTGS2—kidney cancer	3.51e-06	0.000105	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PTEN—kidney cancer	3.06e-06	9.14e-05	CbGpPWpGaD
Rivaroxaban—CYP3A5—Metabolism—PIK3CA—kidney cancer	2.87e-06	8.54e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—POMC—kidney cancer	2.71e-06	8.09e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTGS2—kidney cancer	2.17e-06	6.45e-05	CbGpPWpGaD
Rivaroxaban—ABCB1—Metabolism—PIK3CA—kidney cancer	2.16e-06	6.45e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PTEN—kidney cancer	1.89e-06	5.63e-05	CbGpPWpGaD
Rivaroxaban—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.33e-06	3.97e-05	CbGpPWpGaD
